Maridebart Cafraglutide (MariTide)

Amgen

Maridebart cafraglutide, developed by Amgen and widely known by its program name MariTide (AMG 133), takes an unusual approach to incretin biology. It is a conjugate: a monoclonal antibody that blocks the GIP receptor, linked to GLP-1 peptide agonist molecules. So rather than agonizing both incretin receptors the way tirzepatide does, MariTide agonizes GLP-1 while antagonizing GIP — a deliberately different bet on how to combine these pathways for weight loss. Its antibody backbone gives it a long duration of action, which is the other headline feature: it is being developed for dosing as infrequently as about once a month, far less often than weekly injectables. In Phase 2 studies in obesity, MariTide produced substantial weight loss over roughly a year, and Amgen has continued into a broad late-stage program in obesity and type 2 diabetes. The GIP-antagonist-plus-GLP-1-agonist design is scientifically interesting precisely because it contradicts the GIP-agonist logic of tirzepatide, and the field is watching to see how efficacy, tolerability, and dosing convenience balance out. MariTide is investigational and not approved anywhere; it is not legally available for purchase and is documented here as an educational reference on a distinctive next-generation obesity drug. Gastrointestinal effects during initiation are the main reported tolerability issue.